IEKView：Toward Precision Medicine; A Niche for Taiwanese Players
Since the phrase “precision medicine” was mentioned in 2011 by the United States National Research Council (NRC) in its report "Toward Precision Medicine”, the US, UK, China, France, and Korea have directed significant investments in research and infrastructure related to precision medicine. In July 2017, the Food and Drug Administration (FDA) approved the first companion diagnostic product centered on Next Generation Sequencing (NGS), marking the beginning of the precision medicine era with gene sequencing results being used as the basis of medication decisions.
The modern medical system administers treatments based on symptom descriptions and the findings of routine examinations. This approach can deal with most illnesses but has been ineffective in terms of early diagnostics, precise treatment and risk control for genetic diseases, cancers, communicable and chronic diseases.